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Abstract
Background: UK-wide national clinical guidelines promote routine 6-month post-stroke follow-up assessment.
However, as part of this 6-month assessment little information is gathered from the patient’s perspective. The
means of collecting this patient-centred information might be served best by a patient-reported outcome measure
(PROM) at the 6-month assessment time point. Currently, four different methods of 6-month follow-up assessment
occur; the most common being face-to-face interview followed by telephone interview, postal questionnaire and
online questionnaire. Therefore, this study will investigate if the acceptability of telephone, online or postal
administration of a PROM at the 6-month post-stoke time point is not inferior to face-to-face administration.
Methods/design: A UK multicentre, blinded (analyst and researcher), pragmatic, non-inferiority study, with 80%
power using a 2.5% non-inferiority margin was designed to compare the acceptability of three modes of
administration (telephone interview, postal questionnaire and online questionnaire) compared with face-to-face
interview administration of a PROM. We plan to approach and randomise a minimum of 808 potentially eligible
participants, 202 participants per group.
Discussion: The aim of this ongoing research is to understand if there is a difference between face-to-face
administration and the other three methods of administering a PROM as a patient-centred supplement to the
6-month review for stroke survivors. In utilising a pragmatic design, it is believed that this study will offer UK wide
generalisable results, of the acceptability of the methods under investigation, to inform clinicians and
commissioners of stroke services.
Trials registration: ClinicalTrials.gov: NCT03177161. Registered on 6 June 2017.
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Background
Patient-reported outcome measures (PROMs) are stan-
dardised and validated questionnaires developed for the
purpose of gathering outcome data from the patient’s
perspective [1]. PROMs have come to play an increas-
ingly important role in both clinical practice and re-
search [2–5]. In the present clinical and research climate
there are several generic (health condition non-specific)
health-related quality-of-life measures available such as
the EuroQol 5D (EQ-5D) [6] or the Short Form 36
(SF-36) [7]. These quality-of-life PROMs are currently
used regularly in research studies to evaluate the effective-
ness of interventions post stroke [8] and are integrated
into healthcare systems for use in clinical settings [1].
However, there is currently no conclusive evidence re-
garding the best method of administration of a PROM
with stroke survivors. Potential methods of administra-
tion include face-to-face, telephone, online and via the
post. This choice of comparators is supported by the
findings of the Sentinel Stroke National Audit
Programme (SSNAP) [9], which found that all four
methods of administration are utilised for 6-month
post-stroke follow-ups, with face-to-face follow-up being
the most common method.
PROMs response rates post stroke are mostly reported
as secondary outcomes, in studies which concentrate on
either the development of new PROMs or the reliability
and/or validity of PROMs in specific conditions. In those
studies that report response rate as a primary outcome,
a large variability exists in the response rates reported
from 70.1% [10] for a study by Lannin et al. (2013) com-
paring the cost-effectiveness of telephone vs mail
methods of follow-up for the Australian National Stroke
Registry to 45% [11] for a study by Duncan et al. (2005)
examining response rate for the Stroke Impact Scale
[12] when administered via mail or telephone methods
in veterans. Recently, a cohort study conducted in the
London area by Peters et al. (2014) examining PROMs
collection by post, in primary care, for those with a
long-term condition, received a response rate of 36.4%
[13] for stroke survivors. Thus, with large levels of vari-
ability in response rates of previous studies this study
has opted for a pragmatic design across a large number
of research sites covering rural and urban populations.
The PROM to be utilised in this study is the
Patient-reported Outcomes Measurement Information
System 10 questions (PROMIS-10 Global Health) [14].
This PROM is recommended by the International Con-
sortium of Health Outcomes Measurement (ICHOM) as
part of a proposed standard set of minimum outcome
data for stroke survivors developed by a global team of
stroke specialists [15, 16]. However, the Stroke Standard
Set working group proposes the inclusion of extra
patient-facing health status questions. The first addition
are three questions relating to ambulation, toileting and
dressing that have been adopted from the RiksStroke
(The National Quality Register for Stroke – Sweden)
[17, 18]. Additionally, two further questions on feeding
and communication were developed [15] by the ICHOM
working group for stroke for simple yes/no responses.
The 10 question in PROMIS-10 and separately the three
questions from the RiksStroke and two questions from
the ICHOM Stroke Standard Set will be utilised for this
study. This group of 15 questions will, for ease of refer-
ence, be referred to as Patient-reported Health Status
Questions (PRHSQs).
Therefore, the objective of this research study is to
provide an evidence base for the acceptability of modes
of administration of the PROMIS-10 and five additional
questions for stroke survivors, and to evaluate if online,
postal and telephone modes are not inferior to
face-to-face administration.
Methods/design
Study design
This study is a UK four- arm, pragmatic, multicentre,
non-inferiority randomised controlled trial of the
method of administering the PRHSQs at the 6-month
post-stroke time point (clinically confirmed stroke diag-
nosis ≥ 4 months to ≤ 8 months). The ratio of allocation
is 1:1:1:1, with face-to-face being the method of adminis-
tration against which the non-inferiority of the three
comparator methods (online, postal and telephone) will
be discerned. Participants will be randomly allocated to
one of four methods of administering these 15
Patient-reported Health Status Questions at eligibility
and asked to consent via the post. By virtue of the fact
that any of the four methods under investigation are
established practices in UK stroke services, participants
will not be informed about the other possible modes of
administration. Addressing this research question re-
quires implementation of a Zelen design [19] this ac-
knowledges the issues of contacting patients prior to
obtaining consent. The impact of this design is due to
the nature of the intervention, approaching participants
later than usual, as well as a larger-than-usual sample
size. We acknowledge that informing participants of the
alternative methods of administration may introduce
bias, as the rate of return of the PRHSQs for the differ-
ent assessment methods is the primary outcome of inter-
est. Therefore, participants will knowingly consent to
receive and complete the PRHSQs via a single method
of administration. See Fig. 1 for the participant flow dia-
gram The study protocol was written in full compliance
with the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 [20] and a com-
pleted SPIRIT Checklist and Figure 2013 (Fig. 2) [21] are
available as a supplement (Additional file 1).
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Recruitment
The study has gained acceptance by the Health and Care
Research Wales (HCRW) Clinical Research Portfolio,
thereby allowing for National Health Service (NHS) or-
ganisations in all four devolved nations, via the UK Clin-
ical Research Network Portfolio of studies, to view the
basic study design and to approach the central research
team for permission to open as a research site and con-
duct the research. The researchers will conduct an
open-door policy and will offer the study to any capable
NHS organisation who expresses an interest, based on the
following site inclusion criteria: (1) patients who meet the
study inclusion criteria are routinely under the care of the
principle investigator (PI) at the research site and (2) the
research site is able to facilitate all four arms of the study.
Study setting
The study will be undertaken in 14 centres across
England and Wales. Centres acting as research sites will
be those who were previously involved in potentially eli-
gible participants’ post stroke care. In line with the
time-frame of the study, the majority of potentially eli-
gible participants will reside in the community and will
be anticipating routine clinical follow-up from the cen-
tres acting as research sites.
Study population; inclusion and exclusion criteria –
Inclusion
 Clinically confirmed diagnosis of stroke either
Cerebral Infarct (ICD I63), Cerebrovascular
Haemorrhage (ICD I61) or Stroke, not specified as
haemorrhage or infarction (ICD I64) [22]
 Patients aged ≥ 18 years
 Received a clinically confirmed diagnosis of stroke
within the last 4–8 months (stroke diagnosis ≥
4 months to ≤ 8 months)
Exclusion
 Clinically confirmed diagnosis of a Transient
Ischaemic Attack (ICD G45) [22]
Fig. 1 Participant flow diagram
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 Clinically confirmed diagnosis of a Subarachnoid
Haemorrhage (ICD I60) [22]
Sample size
Using a non-inferiority margin of 2.5%, with a power of
80% and 2.5% significance level and expecting the same
response rate in each group, a minimum of 202 patients
are required per randomised allocation group. Thus, a
minimum total of 808 randomised eligible participants
are necessary for statistical analysis. No adjustment will
be made for carrying out three pair-wise tests. Secondary
outcomes may not necessarily be powered.
Randomisation
The sequence was generated using a varying-sized per-
muted block design, stratified within centre. The se-
quence was concealed by the central research team on a
secure system. The allocation sequences are concealed
from analyst and central research team until planned
unblinding following interpretation of the study findings.
Participants and research staff at the research sites will
not be blinded; however, allocation will be random as to
not introduce bias.
Potentially eligible participants are randomised and al-
located centrally by the research team via e-mail (sent
within a secure e-mail network) for the random
allocation of potentially eligible participants identified
solely via a completely pseudonymous identifier (10-digit
NHS Number). Research sites will then receive the
10-digit pseudonymous identifier, a 6-digit Participant
Research Number (the first two digits being a site identi-
fier and the subsequent four digits referring to the par-
ticipant) and the method assigned to. The use of a
pseudonymous participant research number is to aid
compliance with data governance and to ensure blinding
of the participants to the central research team.
Trial procedure
Potentially eligible participants who have been found eli-
gible by a member of their own clinical care team acting
as principal investigator (PI) at the research site, will
firstly be randomly allocated to each of the four arms of
the study. Following random allocation, potentially eli-
gible participants will be asked to consent by the PI to
the research study based on the method of administra-
tion they have been randomly allocated. The potentially
eligible participants will receive an Invitation Letter, a
Participant Information Sheet and a Consent Form via
the post. The participant facing documentation will in-
vite the participant to consent to the study and receive
their 6-month review and the PRHSQs via one of the
four methods they have previously been randomly
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure
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allocated. Additionally, a proxy consent option is noted
in the Participant Information Sheet and Consent Form,
thereby allowing for a designee to offer consent on be-
half of the participant via the principles of informed con-
sent if the participant requires physical assistance to
complete the questionnaire.
Following the initial contact, participants who have
not responded will be contacted a second time; two
working weeks following the dispatch of the first letter.
The second contact will contain the same information as
the initial contact (Invitation Letter, Participant Informa-
tion Sheet and Consent Form). Potentially eligible partic-
ipants will be given a further four working weeks to
reply to the second invitation to participate. If no con-
sent is returned, the potentially eligible participant will
be assumed not to wish to take part and will not be
asked to complete the PRHSQs.
For all potentially eligible participants who are rando-
mised and invited to participate in the study, we will col-
lect a range of background demographic data and a
small number of routinely collected health-related data.
See Table 1 for details of data for collection.
All demographic data and routinely collected clinical
data will be stored against a Participant Research Num-
ber in the research data base. Personally identifiable in-
formation will only be stored at the research sites and
will not be stored for those who do not offer informed
their consent before the cut-off period of 4 weeks fol-
lowing the posting of the second letter Therefore, no
personally identifiable information will be held by the
central research team.
All consented participants will receive the PRHSQs.
The PI at site as a member of both the research team
and the participant’s own care team will be responsible
for arranging or delegating the completion of the ques-
tionnaires between 4 and 8 months post stroke. There
are schema for each method by which the PI must abide;
however, the methodologies for all four methods of ad-
ministration differ slightly and are as follows:
Face-to-face interview
As part of their routine care, the consented participants
will receive a 6-month post-diagnosis review appoint-
ment with either a clinical nurse specialist (CNS) in
stroke or their clinician. During the 6-month post-stroke
review appointment the PRHSQ will be administered by
a member of the research team. If participants fail to at-
tend the designated appointment they will not be con-
tacted as part of the study but may potentially be
followed up by their own care team at a later date.
Telephone interview
The consented participants will receive through the post
an appointment time to receive a telephone interview
for the 6-month post-diagnosis review appointment with
either a CNS in stroke or their clinician. During the
6-month post-stroke review appointment the PRHSQ
will be administered by a member of the research team.
If participants fail to meet the agreed appointment, they
will not be contacted again by the research team, but
may potentially be followed up by their own care team
at a later date.
Postal questionnaire
The consented participants will receive a paper version
of the PRHSQ. In addition, participants will receive a
pre-paid envelope to return it to the research team. The
questionnaire will be answered and filled in by either the
participant or designated proxy if the participant is un-
able to physically complete the questionnaire. If partici-
pants fail to respond, they will not be contacted again by
the research team, but may potentially be followed up by
their own care team at a later date.
Table 1 Demographic and routine clinical data for collection
Demographic data Routinely collected clinical data
Date of birth
DD/MM/YYYY
Classification of stroke:
Cerebral Infarct (ICD I63)
Cerebrovascular Haemorrhage (ICD I61)
Stroke – not specified as Haemorrhage or Infarction (ICD I64)
Sex Date of index event (date of stroke)
Individual National Institutes of Health Stroke Score (NIHSS) on admission:
0–42District-level postcode –
First 3–4 digits of a
UK post code
Treated with thrombolysis?
Yes / No
Modified Rankin Score on discharge or transfer from stroke unit:
0–6
Clinically confirmed diagnosis of aphasia as sequela of ICD I63, I61 or I64?:
(data collected at 3 sites within a single Health Board only)
Yes / No
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Online questionnaire
The consented participants will receive a postal invita-
tion to access a secure online version of the PRHSQ via
a secure web address (Bristol Online Survey – https://
www.onlinesurveys.ac.uk/).. The online questionnaire
will be answered and filled in by either the participant or
designated proxy if the participant is unable to physically
complete the questionnaire. If participants fail to
complete the online questionnaire, they will not be con-
tacted again by the research team, but may potentially
be followed up by their own care team at a later date.
Data management
Data will be collected at the research sites until February
2018. Potentially eligible participants who do not
respond or consent will not be excluded from data ana-
lysis of their demographic and routinely collected
non-identifiable clinical data as this data is essential for
the determination of acceptability of the methods under
investigation. However, individuals who do not consent
will not receive the PRHSQs.
Two levels of data management exist for this research
study. The first level is that of the individual research
site which will have access to identifiable patient data.
This will allow the site to invite potentially eligible par-
ticipants and to contact participants who consent to re-
ceive the PRHSQs via the method randomly assigned.
Following completion of the PRHSQs the anonymous
data received from the two self-administered question-
naires (postal or online) will be populated in the re-
search data base against the corresponding Participant
Research Number as detailed on the returned PRHSQs.
The data from the two administered methods (face-to--
face or telephone) will be captured via anonymised
PRHSQs, identified solely by the Participant Research
Number.. Data is to be initially coded and entered into a
site level data base. The data base has been developed
using Microsoft Excel 2013 to support ‘data validation’
and will not accept any data entered outside pre-defined
ranges for each discrete data value to be collected. Add-
itionally, ‘conditional formatting’ will be utilised to en-
sure that double entry is minimised..
The second level of data management is that of the
central research team. No personally identifiable infor-
mation will be transferred or held in the central research
data base. Research sites will transfer data to the re-
search team using the Participant Research Number as
the unique discriminator. Data quality will be ensured
by the trial statistician (Dr. Ben Carter, Senior Lecturer
in Biostatistics, King’s College London) by conducting
central data verification prior to data base lock. Data
queries arising from data verification procedures will be
submitted to sites in writing and sites will have two
working weeks to respond in full.
All data will be handled by research sites and by the cen-
tral research team in accordance with the Data Protection
Act (1998) [23]. Subsequent to the closure of the study all
trial materials will be archived for a period defined by
Good Clinical Practice (ICH-GCP). The study will be con-
ducted in accordance with the Declaration of Helsinki.
Monitoring
Site monitoring visits will occur throughout the conduct
of the study. These monitoring visits will be conducted
by members of the central research team and will ensure
the correct conduct of the study and will identify any
protocol deviations. Furthermore, site monitoring visits
will support sites and will offer the opportunity for the
central research team to improve the conduct of the
study by identifying needs at the research site and offer
any clarification or training necessary. The principal in-
vestigators (PIs) at research sites are responsible for
monitoring protocol deviations and sites are required to
report all deviations via the protocol deviation form. All
deviations will be monitored and assessed by the central
research team. Following assessment, corrective and pre-
ventative actions will be disseminated to the sites.
Adverse events
All harms will be reported utilising an adverse and serious
adverse event (AE, SAE) form included in the research site
file, which will be disseminated to all research sites during
site initiation visits. We do not anticipate any trial-related
AEs; however, sites will collect and report all AEs and
SAEs to the central research team within 24 h of discovery
as per the Health and Care Research Wales guidelines. In
the event of a trial-related AE or SAE the research site will
escalate this to their local NHS R&D department, National
Research Governance Organisation and to the chief inves-
tigator (CI). Additionally, all PRHSQs can be unblinded
via the research sites in the rare event that a concern for
patient safety or the safety of others is identified.
Outcomes
Primary outcome
 The proportion of individuals eligible for the study
who return the method specific PRHSQs in each of
the four study arms (postal, online, face-to-face and
telephone)
Secondary outcomes
 The proportion of individuals eligible for the study
who return the method specific PRHSQs in each of
the four study arms (postal, online, face-to-face and
telephone) for individuals with communication is-
sues (i.e. aphasia)
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 The proportion of individuals eligible for the study
who return the method specific PRHSQs in each of
the four study arms (postal, online, face-to-face and
telephone) by stroke severity as defined by individual
NIHSS on admission
 The proportion of individuals eligible for the study
who return the method-specific PRHSQs in each of
the four study arms (postal, online, face-to-face and
telephone) by stroke type; Cerebral Infarct (ICD I63),
Cerebrovascular Haemorrhage (ICD 161) or Stroke,
not specified as haemorrhage or infarction (ICD I64)
Statistical analysis
Analysis of the primary outcome
We will carry out a difference of two proportions between
the three intervention groups (postal, telephone or online)
verses face-to-face administration, with a 2.5%
non-inferiority margin. The three comparisons will be ad-
justed using a Holm [24] multiplicity adjustment, with a
two-sided alpha = 0.05. The analysis will be presented as a
difference with an associated 95% confidence interval (CI).
Analyst and researchers blinding to the allocation will
remain in place until interpretation of the primary and
secondary outcomes are agreed. Following un-blinding
of the allocation, difference will be generated in the
three comparator allocation groups, and face-to-face
completion rate, and will include the non-inferiority
margin of 2.5%, as our primary analysis.
Secondary analysis of the primary outcome
We plan to repeat the primary analysis after adjustment
for: age; sex; National Institutes of Health Stroke Score
(NIHSS) on admission and stroke type (Haemorrhagic
or Ischaemic).
Analysis of the secondary outcomes
Continuous data will be summarised descriptively, and
also with a general linear model, and adjusted for patient
age and sex. Dichotomous data will be summarised de-
scriptively and will analysed using a logistic regression
adjusted for: patient age and sex.
We note that many data will be gathered relating to the
questionnaire itself. This useful clinical data warrants pub-
lication in its own right; however, it is not the focus of this
study and will form a separate stand-alone analysis.
Missing data and analysis population
We will be reporting using a complete case analysis. Due
to the nature of the research question, we are expecting
missing data, and anticipate that this will be not missing
at random. We will describe patterns of missing data.
However, the primary objective of this study is to ascer-
tain if the missing data is systematically more likely in
the comparator groups, compared to the face-to-face al-
location group.
Non-inferiority margin
Utilising unpublished routinely collected clinical data ap-
proximately 85% of follow-up appointments for all pa-
tients, who would meet the inclusion criteria, return for
face-to-face administration of their 6-month post-stroke
follow-up assessment at the ≥ 4-month to ≤ 8-months
post-diagnosis time point. The reason for this high level
of face-to-face follow-up is not grounded on evidence,
however, disability and communication issues post
stroke may have a role in the choice of this method.
Nevertheless, there is a significant cost implication in the
choice of method for follow-up as evidenced in a study by
Lannin et al. (2013) investigating the cost-effectiveness of
telephone vs mail methods of follow-up for the Australian
National Stroke Registry [10].
Alongside the National Institute for Health and Care
Excellence (NICE) accredited RCP stroke guidelines [25],
a non-inferiority margin of 2.5% was decided upon as
the maximum tolerated acceptable reduction in accept-
ability, alongside conflicting resource allocation and of-
fering flexibility of patients to undergo follow-up.
Trial governance
Trial management group
The study has been delivered to the highest standard over-
seen by the Trial Management Group (TMG). The TMG
met routinely to develop and approve the following: trial
documents (Participant Information Sheet, Invitation
Letter, and Protocol), Randomisation Protocol; trial data-
base; Case Report Forms. The TMG will be convened rou-
tinely to discuss trial-related issues as they arise (e.g.
protocol deviations, AEs and SAEs); changes to the proto-
col; data management plan and statistical analysis plan.
Trial Steering Committee
The study is to be overseen by a Steering Committee
composed of Dr. Manju Krishnan (Clinical Lead and
Consultant Stroke Physician Abertawe Bro Morgannwg
University Health Board and Deputy HCRW Stroke
Research Lead) as chair, lay members, independent clin-
ical and research specialists and key stakeholders. The
Steering Committee will be responsible for examining
research progress, monitoring progress against estab-
lished timelines and monitoring recruitment, completion
and follow-up rates. Meetings will take place quarterly
and all recommendations arising from the Steering
Committee will be acted upon immediately. Moreover,
the Steering Committee will reserve the right to request
and receive interim reports between quarterly meetings.
The nature and design of the trial does not necessitate
the creation of an additional Data Management
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Committee to supplement the work of the Trial Steering
Committee. Therefore, the Trial Steering Committee will
have oversight across the study, including data monitor-
ing and data management.
Discussion
This pragmatic randomised controlled trial will provide
insight into the optimal method of PROM delivery in
stroke survivors and also inform the choice of delivery
method across other chronic disease conditions, especially
conditions associated with chronic physical disability. The
choice of a pragmatic study design, whilst offering good
generalisability and the testing of a hypothesis under as
near to ‘real-world’ conditions as is possible, can and will
offer substantial challenges. The ‘natural’ organisational
variances of each research site, require careful and thor-
ough discussions to ensure that research is not disruptive
to routine clinical work and that the research procedures
outlined within the protocol are adhered to.
We assume a possibility that the pragmatic design of
the research study will not be accessible to all individuals
post stoke. Nevertheless, all eligible individuals are to be
accounted for in data analysis. It is believed, that this
will offer possible correlations as to why certain demo-
graphic and clinical features relate to the number of
consented participants for each allocated method.
The benefits of this study, to stroke survivors is in the
fact that they will offer clinicians and healthcare com-
missioners early evidence as to which method they find
most acceptable, when compared against the most com-
monly commissioned approach. Moreover, due to the as-
sumption that data is missing not at random, those who
do not respond offer useful data. Therefore, any actions
taken on the basis of the final analysis of this study can
do so in the knowledge that those actions are based on
the preferences of all the eligible stroke survivors
approached for the study.
Dissemination
We plan to disseminate the findings of the study via a
peer-reviewed academic journal. The findings of which
will be cascaded to all research sites and disseminated
from the research sites to participants. The published
findings will adhere to the Consolidated Standards of
Reporting Trials (CONSORT) randomised control trial
reporting guidelines [26, 27]. In addition, the published
findings will adhere to both the CONSORT extension
relating to non-inferiority and equivalence trials [28] and
the extension relating to pragmatic trials [29].
Trial status
Recruitment commenced in July 2017 and is planned to
continue until February 2018. Protocol Version: 1.0
Date: 10 April 2017.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents. (DOC 121 kb)
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